Phase 2 N=227 Higher Dose Intradermal H5 Vaccine
Influenza
Primary: Number of Participants Achieving a 4-fold or Greater Increase in HAI Antibody Titers After Dose 2 — 47; 40 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=103 Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children
Meningitis · Meningococcemia
Primary: Geometric Mean of Antibody Titers (GMTs) as Measured by Serum Bactericidal Assay (SBA) at Baseline (Day 0) and Day 28 Post-vaccination. — 136.33; 99.66; 11404.16; 199.31…
Phase 2 N=58 A Lifestyle Change Program to Prevent Type 2 Diabetes
Prediabetes
Primary: Number of Participants Who Met Weight Loss Goal of 5% Weight Loss — 3; 6 participants — p=0.08
Phase 2 N=85 Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix
Infertility, Female
Primary: Coefficient of Variation of Follicular Sizes on Stimulation Day 1 (Follicles ≥ 2 mm) — 36.7; 39.2 Percentage
Phase 2 N=21 A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
Fabry Disease
Primary: Globotriaosylceramide (GL-3) Clearance in Kidney Interstitial Capillary Endothelium — 3; 21; 18; 17 Participants
Phase 2 N=20 Laxative Effectiveness of a Phytotherapeutic Tea
Chronic Constipation
Primary: Intestinal Transit Time — 42.3; 15.66 hours — p=<0.001
Phase 2 N=189 Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer
Prostate Cancer
Primary: Number of Patients With Testosterone <=0.5 Nanograms/Milliliter From Day 28 to Day 364 — 17; 21; 26; 27 participants
Phase 2 N=180 Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients
Prostate Cancer
Primary: Time From Dosing Until Testosterone Levels >0.5 ng/mL — 84; 63; 70; 140 days — p=0.0000586
Phase 2 N=129 The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Testosterone <0.5 Nanogram/Milliliter — 38; 32; 27; 38 participants
Phase 2 N=124 Trial to Describe the Safety and Immunogenicity of Fluzone®
Influenza
Primary: Solicited Injection Site and Solicited Systemic Reactions Post-vaccination. — 62; 57; 0; 9 Participants
Phase 2 N=50 Gemcitabine in Ovarian Cancer
Ovarian Cancer
Primary: Best Overall Tumor Response — 6; 25; 10; 5 participants
Phase 2 N=36 A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia
Diabetes Mellitus, Type 2 · Insomnia
Primary: Sleep Efficiency — 79.5; 83.1 Percentage of time asleep — p=0.04
Phase 2 N=49 Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Tumor Response at End of Treatment — 1; 18; 3; 1 participants
Phase 2 N=12 A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,
Snake Bite · Blood Coagulation Disorders
Primary: Detection of Plasma Venom Levels During the Post Acute Treatment Period. — 0; 4; 6; 2 participants
Phase 2 N=35 Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
Major Depressive Disorder (MDD)
Primary: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 8 — -8.4 Scores on a scale